Microsoft has contributed to the artificial intelligence technology developer's OpenAI Startup Fund, two years after investing $1bn in the company.

Zymergen has purchased Lodo Therapeutics, which is advancing Rockefeller research, for an undisclosed sum five years after the company raised its only funding round.

The GlaxoSmithKline and Celgene-backed immunotherapy developer has revealed its intention to float on the Nasdaq Global Market.

The Pfizer, GlaxoSmithKline, Novartis, AbbVie and Astellas-backed oncology therapy developer is set to go public through a reverse takeover.

SoftBank Vision Fund 2 led the e-commerce holding company's latest round, reportedly the largest series A ever closed by a US-based company.

The payment software provide's shared popped on their first day after an IPO that followed two Goldman Sachs-backed funding rounds.

Alexandria Venture Investments has participated in an $88.9m round which has pushed the biotech developer's total funding past $142m.

Lilly Asia Ventures has returned to back the immuno-oncology therapy developer’s latest round, eight months after participating in the company’s series B.

Shionogi has joined subsidiaries of Merck Group and Amgen in the equity portion of a series D round for the digital therapeutics developer.

UC San Francisco spinout Effector Therapeutics is set to go public through a reverse merger with Locust Walk Acquisition Corp that includes a $60m PIPE financing.